Advanced Prostate Cancer Treatment Options: New Therapies, Genetic Testing, and Emerging Research

In this educational presentation, medical oncologist Dr. Mark Pomerantz of Dana-Farber Cancer Institute and Harvard Medical School provides an in-depth overview of treatment options for advanced and metastatic prostate cancer. Using a real patient case study, Dr. Pomerantz explains how prostate cancer progresses, when treatments are used, and how recent medical advances are helping men live longer with the disease. Topics covered include hormone therapy, androgen receptor-targeted treatments, chemotherapy, immunotherapy, radiopharmaceuticals, PARP inhibitors, genetic testing, and the importance of clinical trial participation. The discussion also explores emerging research on treatment outcomes in African American men and the growing role of precision medicine in prostate cancer care. Key Topics: ● Metastatic and castration-resistant prostate cancer ● Hormone therapy and androgen receptor-targeted treatments ● Abiraterone, enzalutamide, apalutamide, and darolutamide ● Chemotherapy options including docetaxel and cabazitaxel ● Immunotherapy and Provenge® ● Radiopharmaceutical treatments and lutetium-177 ● PARP inhibitors and BRCA gene mutations ● Genetic testing and precision medicine ● Clinical trials and African American participation ● Emerging therapies and future treatment directions This presentation was recorded as part of PHEN’s educational programming focused on empowering patients, caregivers, and advocates with the latest information on prostate cancer treatment and research.